Jeremie Calais, MD, MSc, University of California, Los Angeles, CA, provides an overview focusing on the incorporation of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) into clinical practice for the treatment of prostate cancer (PC). With the recent approval of lutetium Lu 177 (177Lu) vipivotide tetraxetan for metastatic castration-resistant PC (mCRPC), the utilization of RLT is expected to increase. The authors suggest a framework for establishing RLT centers and discuss key elements to consider. They emphasize the importance of a well-trained multidisciplinary team, efficient administrative systems for scheduling and reimbursement, and patient monitoring for safety and efficacy. The review provides insights based on a search of PubMed and Google Scholar, as well as the authors' clinical experience. Overall, it highlights the need for careful planning and organization to ensure the successful implementation of RLT for PC treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.